<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421289</url>
  </required_header>
  <id_info>
    <org_study_id>ID 05-56-13</org_study_id>
    <nct_id>NCT02421289</nct_id>
  </id_info>
  <brief_title>Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients</brief_title>
  <official_title>Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients in a Prospective Randomized Controlled Trial: a Proof-of-concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genetic polymorphisms of cytochrome P450 2B6 (CYP2B6) are associated with lower rate of EFV
      metabolism and lead to high exposure, as well as a higher risk of neuropsychiatric adverse
      event especially homozygous variant CYP2B6 *6/*6. This trial was designed to compare the
      proportion of patients who had undetectable HIV RNA at 24 weeks after ART initiation between
      patient who did CYP 2B6 guided EFV dose and who did not.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV RNA</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Cytochrome P-450 CYP2B6</condition>
  <condition>Efavirenz</condition>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>CYP2B6 guided group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were assigned to perform CYP2B6 study before ART initiation. If CYP2B6 *6/*6 was found in CYP2B6 *6/*6, the patients will be initiated a low dose of 400 mg of efavirenz (2 tablets of 200 mg) with tenofovir 300 mg and lamivudine 300 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients were promptly ART initiation regardless CYP2B6 results. Treatments were efvirenz 600 mg, tenofovir 300 mg and lamivudine 300 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>There will be adjusted dose of efavirenz in CYP2B6 guide group</description>
    <arm_group_label>CYP2B6 guided group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.</description>
    <arm_group_label>CYP2B6 guided group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CYP450 2B6</intervention_name>
    <description>All patients will be monitored drug level which should be in therapeutic level.</description>
    <arm_group_label>CYP2B6 guided group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years old

          -  Anti-HIV positive

          -  Naïve to antiretroviral drugs

          -  Meet the criteria to start ART to Thai National guidelines

          -  Sign inform consent

        Exclusion Criteria:

          -  Body mass index (BMI) &gt;25 kg/m²

          -  Pregnant women or breastfeeding

          -  Received drugs that may have interaction with EFV e.g. rifampicin, fluconazole
             (400-800 mg), ergot alkaloid, midazolam, triazolam, ritonavir, carbamazepine,
             phenytoin, phenobarbitone, St John's Wort

          -  Having active opportunistic infections e.g. tuberculosis, cryptococcosis,
             histoplasmosis, penicillosis

          -  Hepatic dysfunction as indicated by:

          -  Transaminases &gt;5-10 × the upper limit of normal

          -  ALP &gt;5-10 × the upper limit of normal

          -  Total bilirubin &gt;2.5-5 × the upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pansachee Damronglerd, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of medicine Ramathibodi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pansachee Damronglerd, M.D.</last_name>
    <phone>+66 8515-6188</phone>
    <email>joh_pum@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sasisopin Kiertiburanakul, M.D., M.H.S.</last_name>
    <email>sasisopin@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of medicine Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pansachee Damronglerd, M.D.</last_name>
      <phone>+66 85-015-6188</phone>
      <email>joh_pum@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>August 2, 2015</last_update_submitted>
  <last_update_submitted_qc>August 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Pansachee DAMRONGLERD</investigator_full_name>
    <investigator_title>Ramathibodi Hospital</investigator_title>
  </responsible_party>
  <keyword>CYP2B6 polymorphism</keyword>
  <keyword>efavirenz</keyword>
  <keyword>Thai</keyword>
  <keyword>HIV-infected patient</keyword>
  <keyword>pharmacogenomic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 29, 2016</submitted>
    <returned>June 6, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

